| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...618164C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0018164 |
| P932 | PMC publication ID | 3071718 |
| P698 | PubMed publication ID | 21483676 |
| P5875 | ResearchGate publication ID | 51042441 |
| P50 | author | Sabine Yerly | Q63111732 |
| Giuseppe Pantaleo | Q88061163 | ||
| Sabine Kinloch-de Loes | Q98841156 | ||
| P2093 | author name string | John Sweeney | |
| Cristina Cellerai | |||
| Ian Williams | |||
| Margaret Johnson | |||
| Alexandre Harari | |||
| Jonathan Ainsworth | |||
| Hans Stauss | |||
| Andrew Freedman | |||
| Anne Carroll | |||
| Anna-Maria Geretti | |||
| Thynn Yee | |||
| P2860 | cites work | DNA sequencing with chain-terminating inhibitors | Q22066207 |
| Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection | Q24536249 | ||
| HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors | Q24676982 | ||
| MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0 | Q26778434 | ||
| The influence of HLA genotype on AIDS | Q28202903 | ||
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice | Q28594763 | ||
| A whole-genome association study of major determinants for host control of HIV-1 | Q29614891 | ||
| HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
| Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major | Q29619125 | ||
| HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| T-cell quality in memory and protection: implications for vaccine design | Q30014840 | ||
| T-cell epitope mapping by flow cytometry | Q32040492 | ||
| Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells | Q33539769 | ||
| Polyfunctional T lymphocytes are in the peripheral blood of donors naturally immune to coccidioidomycosis and are not induced by dendritic cells | Q33557707 | ||
| Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control | Q33594461 | ||
| Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression | Q33769360 | ||
| HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. | Q33772204 | ||
| Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy | Q33843388 | ||
| Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects | Q33949316 | ||
| Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells | Q33981572 | ||
| Cellular immune responses to HIV. | Q34223069 | ||
| Impact of MHC class I diversity on immune control of immunodeficiency virus replication | Q34235198 | ||
| Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV | Q34514374 | ||
| Lymphocyte-mediated cytotoxicity. | Q34542250 | ||
| Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover | Q34692601 | ||
| Re-emergence of HIV after stopping therapy | Q59060012 | ||
| A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays | Q59650911 | ||
| HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors | Q78342521 | ||
| Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions | Q81913313 | ||
| Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection | Q84409867 | ||
| Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy | Q45721932 | ||
| Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study | Q45747964 | ||
| HIV-1 and immune control: can we change the course of HIV-1? | Q46166326 | ||
| Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. | Q46738531 | ||
| Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection | Q47309381 | ||
| Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. | Q51888711 | ||
| Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. | Q53736890 | ||
| Preservation of T Cell Proliferation Restricted by Protective HLA Alleles Is Critical for Immune Control of HIV-1 Infection | Q56600656 | ||
| Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions | Q57226476 | ||
| CD8+ T-cell responses to different HIV proteins have discordant associations with viral load | Q57259602 | ||
| Predictors of Virological Outcome and Safety in Primary HIV Type 1-Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005 | Q58291249 | ||
| Cytotoxic T lymphocytes: all roads lead to death | Q34716318 | ||
| Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals | Q34762506 | ||
| Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection | Q35023986 | ||
| Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes | Q35110576 | ||
| Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication | Q35158133 | ||
| HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype | Q35749755 | ||
| Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load | Q35784804 | ||
| Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know | Q35852348 | ||
| Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype | Q36022184 | ||
| Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort | Q36280900 | ||
| Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy | Q36304297 | ||
| Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication | Q36315510 | ||
| Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma | Q36368808 | ||
| HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity | Q36371562 | ||
| Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. | Q36452614 | ||
| Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4+T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2 | Q36474240 | ||
| Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy | Q36498230 | ||
| Functional signatures of protective antiviral T-cell immunity in human virus infections. | Q36529008 | ||
| Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells | Q36540008 | ||
| Polyfunctional T cell responses are a hallmark of HIV-2 infection | Q36618086 | ||
| Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy | Q36950611 | ||
| HIV rebounds from latently infected cells, rather than from continuing low-level replication | Q36954950 | ||
| Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control | Q37054526 | ||
| Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure | Q37127942 | ||
| Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. | Q37410726 | ||
| HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals | Q37771138 | ||
| Persistent immune activation in HIV-1 infection is associated with progression to AIDS. | Q39060564 | ||
| The CTL's kiss of death | Q40399827 | ||
| Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection | Q40404185 | ||
| Predictors of Plasma Human Immunodeficiency Virus Type 1 RNA Control after Discontinuation of Highly Active Antiretroviral Therapy Initiated at Acute Infection Combined with Structured Treatment Interruptions and Immune‐Based Therapies | Q40548790 | ||
| HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition | Q41966337 | ||
| Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). | Q42691966 | ||
| Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. | Q43869599 | ||
| Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection | Q43901814 | ||
| Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection | Q43986794 | ||
| Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. | Q44291572 | ||
| Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus | Q45404246 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | e18164 | |
| P577 | publication date | 2011-04-05 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors | |
| P478 | volume | 6 |
| Q42562453 | A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. |
| Q35323147 | A lower viral set point but little immunological impact after early treatment during primary HIV infection |
| Q36087130 | Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection |
| Q34490157 | Autologous HIV-1 clade-B Nef peptides elicit increased frequency, breadth and function of CD8+ T-cells compared to consensus peptides |
| Q47580241 | CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective. |
| Q30432007 | CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis |
| Q38067705 | Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers |
| Q38433251 | Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. |
| Q26998898 | Developing Combined HIV Vaccine Strategies for a Functional Cure |
| Q64286953 | Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors |
| Q33775397 | French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults |
| Q40479645 | HLA-G+ HIV-1-specific CD8+ T cells are associated with HIV-1 immune control. |
| Q38433342 | High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection |
| Q38000415 | IFN-α and TRAIL: a double edge sword in HIV-1 disease? |
| Q36311695 | Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. |
| Q35795271 | Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells |
| Q40869409 | Key role played by the gut associated lymphoid tissue during human immunodeficiency virus infection |
| Q38800533 | Kill: boosting HIV-specific immune responses |
| Q38086432 | Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses |
| Q45930474 | Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. |
| Q36509593 | Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification |
| Q42252024 | Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans |
| Q38263002 | Modulation of Regulatory T-Cell Subsets in Very Long-Term Treated Aviremic HIV(+) Patients and Untreated Viremic Patients. |
| Q51839003 | Modulation of polyfunctional HIV-specific CD8 T cells in patients responding differently to antiretroviral therapy. |
| Q41181556 | Multifarious immunotherapeutic approaches to cure HIV-1 infection |
| Q35861157 | Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties |
| Q34819446 | Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells |
| Q28649848 | Review: Influence of ART on HIV genetics |
| Q35746522 | SIV-infection-driven changes of pattern recognition receptor expression in mesenteric lymph nodes and gut microbiota dysbiosis |
| Q35857623 | Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward |
| Q33586581 | The detection and management of early HIV infection: a clinical and public health emergency |
| Q41630590 | Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection |
Search more.